KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Randomized 87 patients to date in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED) -- -- ...
Nature10y
From cells, secrets of the secretome leak out
Secreted proteins from all cells make up a rich, complex subset of molecules referred to by scientists as the 'secretome'. On 9 June, at the 'Cancer Proteomics 2009' meeting held by the European ...
MPR4d
Neonatal Cardiac Progenitor Cell Therapy Fast Tracked for HFpEF
The Food and Drug Administration (FDA) has granted Fast Track designation to STM-01 for the treatment of heart failure with preserved ejection fraction ...
Yahoo Finance6d
Secretome Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1 Study of STM-01 in Heart Failure with Preserved Ejection Fraction
PLANO, Texas & BALTIMORE, March 25, 2025--(BUSINESS WIRE)--Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells ...
Morningstar10d
Secretome Therapeutics Granted FDA Fast Track Designation for STM-01, a Neonatal Cardiac Progenitor Cell Therapy for HFpEF
Secretome Therapeutics is developing therapies derived from neonatal cardiac progenitor cells (nCPCs) to address life-threatening cardiovascular diseases and conditions driven by inflammation.
Nature8y
Molecular alterations in bone marrow mesenchymal stromal cells derived from acute myeloid leukemia patients
The contribution of molecular alterations in bone marrow mesenchymal stromal cells (BM-MSC) to the pathogenesis of acute myeloid leukemia (AML) is poorly understood. Thus we assessed genome-wide ...
Joplin Globe11d
Secretome Therapeutics Granted FDA Fast Track Designation for STM-01, a Neonatal Cardiac Progenitor Cell Therapy for HFpEF
Secretome Therapeutics, a pioneering company in the field of regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to STM-01 ...
The Bakersfield Californian10d
Secretome Therapeutics Granted FDA Fast Track Designation for STM-01, a Neonatal Cardiac Progenitor Cell Therapy for HFpEF
Secretome Therapeutics, a pioneering company in the field of regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to STM-01, the ...